ND016

ND016 is a trispecific antibody fragment developed for autoimmune disorders, simultaneously inhibiting the pro-inflammatory cytokines **IL-17A** and **TNF-α** with high potency, while also binding serum albumin to enable convenient dosing and enhanced tissue penetration. Initially discovered by **Numab Therapeutics AG** using their fully human lambda cap™ technology for stable variable domains, it was licensed to **Intarcia Therapeutics Inc.** for worldwide development and commercialization. The monovalent design aims to improve efficacy in conditions like rheumatoid arthritis and psoriatic arthritis compared to standard therapies, with favorable manufacturing properties.[1][4]